Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
Actinium to Highlight Targeted Conditioning Portfolio at —…—… Transplantation & ...
12:00am, Thursday, 13'th Feb 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXEL), Ionis Pharmaceuticals (IONS) and Zogenix (ZGNX).
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Exelixis (EXEL – Research Report),
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
10:50pm, Wednesday, 05'th Feb 2020
Actinium Pharmaceuticals (ATNM) closed at $0.24 in the latest trading session, marking a +1.04% move from the prior day.
Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
01:03pm, Wednesday, 05'th Feb 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO & Investor Conference. Hos
Actinium Pharmaceuticals, Inc. to Present at the ——nd Annual BIO CEO & Investor Conference
12:00am, Wednesday, 05'th Feb 2020Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
10:45pm, Thursday, 30'th Jan 2020
Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $0.26, moving -0.54% from the previous trading session.
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
12:00am, Thursday, 30'th Jan 2020Actinium (ATNM) Upgraded to Strong Buy: Here's Why
05:00pm, Monday, 13'th Jan 2020
Actinium (ATNM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price
12:15pm, Monday, 13'th Jan 2020
Anyone researching Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) might want to consider the historical volatility of...
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to utilize Actinium's Antib
Beyondspring (BYSI) Gets a Buy Rating from William Blair
06:40pm, Friday, 10'th Jan 2020
In a report issued on January 6,
Andy Hsieh
from William Blair reiterated a
Buy
rating on Beyondspring (
BYSI
–
Research Report
). The company’s shares closed last Monday at $17.64.
According to
T
William Blair Sticks to Its Hold Rating for FibroGen (FGEN)
06:40pm, Friday, 10'th Jan 2020
William Blair analyst Andy Hsieh reiterated a Hold rating on FibroGen (FGEN – Research Report) on January 6. The company’s
Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™
12:03pm, Tuesday, 07'th Jan 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that Sandesh Seth, Actinium's Chairman and CEO, will present at the 2020 Biotech Showcase™ being held on January 13-
